SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two OthersZacks Investment Research • 09/02/24
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosisGlobeNewsWire • 09/02/24
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantGlobeNewsWire • 08/08/24
Press Release: Online availability of Sanofi's half-year financial report for 2024GlobeNewsWire • 07/25/24
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel DiseaseBusiness Wire • 07/25/24
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia AGlobeNewsWire • 07/17/24
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US MarketBusiness Wire • 07/10/24